SG3 Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

SG3 Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,878	Closed	-$249K	–	215
2022 Q3	$249K	Buy	+8,878	New	+$290K	0.03%	187

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SG3 Management's AMPH Position: Q4 2022 in Review

SG3 Management sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2022, closing a stake of 8,878 shares — an estimated $249K sold.

SG3 Management first reported a position in AMPH in Q3 2022 and held it in 1 quarter. The position peaked at $249K in Q3 2022. 211 funds tracked by Wall St. Rank hold AMPH as of Q4 2022.

SG3 Management reported no remaining Amphastar Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
SG3 Management sold 8,878 Amphastar Pharmaceuticals shares in Q4 2022, an estimated $249K.
SG3 Management first reported a position in Amphastar Pharmaceuticals in Q3 2022 and held it in 1 quarter.
SG3 Management's Amphastar Pharmaceuticals position peaked at $249K in Q3 2022.
211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.